Lilly Participates in China International Fair for Trade in Services for the Fourth Time, Empowering High-Quality Innovation in China's Pharmaceutical Sector

Ms. Dehran said: "As a global leading pharmaceutical company, Eli Lilly is very honored to participate in this grand event, share the latest innovative achievements and global experiences, and have in-depth exchanges and cooperation with colleagues from all sectors, jointly contributing to the high-quality development of China's healthcare industry. The Chinese market is full of unlimited opportunities, and the favorable policy environment and the vigorous development of local innovation have further strengthened Eli Lilly’s confidence in its development in China. Eli Lilly will continue to support the 'Healthy China 2030' strategy, focus on patients, use innovation and high-quality manufacturing, and is committed to enabling tens of millions of Chinese patients to have a better life."

On the first day of the China International Fair for Trade in Services (CIFTIS), Eli Lilly and Company signed a strategic cooperation memorandum with Xuanwu Hospital, Capital Medical University.Li Ang, Deputy Director of the Beijing Municipal Health Commission; Zhang Jingbo, Director of the Beijing Medical and Health Science and Technology Promotion Center; Guan Zhongjun, Party Secretary of Xuanwu Hospital, Capital Medical University; Dr. Wang Li, Senior Vice President of Eli Lilly and Company and Head of Eli Lilly China Drug Development and Medical Affairs Center, among other important leaders and guests.Attended the signing ceremony, during which both parties had an in-depth exchange on current and future potential drug clinical trial projects. The collaboration between Xuanwu Hospital of Capital Medical University and Eli Lilly and Company extensively covers areas such as Alzheimer's disease, migraine, coronary heart disease, and hematological tumors. In recent years, Eli Lilly and Company has continuously deepened its cooperation with local research institutions and medical organizations in China to accelerate the development and market launch of innovative drugs, enabling Chinese patients to access innovative treatment options earlier and contributing to the high-quality development of China’s biopharmaceutical innovation.

Obesity is a chronic progressive disease that currently affects more than 1 billion people worldwide, and it is projected that by 2035, more than half of the global population will be obese or overweight.^1,2,3However, this chronic disease is often misunderstood by the public, and its diagnosis, medical treatment, insurance, and long-term care levels are far lower than those of other chronic diseases. Obesity can lead to other illnesses, with up to 5 million people dying each year from cardiovascular diseases (CVD), cancer, diabetes, and other chronic diseases attributable to obesity.^3,4,5The average life expectancy of men and women may be reduced by 5.8 years and 7.1 years, respectively, due to obesity.⁶。Eli Lilly and Company is making relentless efforts to develop disease solutions for obese and overweight patients, and is committed to promoting evidence-based treatment models for obesity and ensuring that patients receive appropriate treatment.This year, we have already had innovative drugs approved in China, and we will continue to actively work with the government, industry, and partners to jointly establish a new model for efficient, evidence-based long-term weight management.

As the global population continues to age, Alzheimer's disease has become an increasingly severe global health crisis. It is estimated that 32 million people worldwide are living with Alzheimer's disease and have confirmed amyloid pathology changes.⁷。We believe that the earlier patients are detected and diagnosed, the more likely they are to benefit from new treatments. Early diagnosis and treatment of early symptomsADPatients have the potential to significantly slow disease progression, providing them with valuable time to maintain their independence for a longer period. Eli Lilly and Company is committed to collaborating with China's health system and regulatory authorities to continuously strengthen the diagnosis and treatment system for Alzheimer's disease, aiming for early detection, diagnosis, treatment, and management of the condition.35In recent years, Eli Lilly and Company has invested in the Alzheimer's disease field.80More than billions of dollars, with over110,000 patients participated in the clinical trial, including patients from China.Currently, we have an innovative Alzheimer's disease drug under review and approval by the National Medical Products Administration (NMPA), and we hope it can benefit patients in China as soon as possible.